Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Sci Rep ; 9(1): 17490, 2019 11 25.
Artículo en Inglés | MEDLINE | ID: mdl-31767915

RESUMEN

Proton pump inhibitors (PPIs) alter the composition of the intestinal microbiome, exacerbating indomethacin (IND)-induced small intestinal damage. Vonoprazan fumarate inhibits gastric acid secretion using a different mechanism from PPIs. We investigated the effects of both drugs on the intestinal microbiome and IND-induced small intestinal damage. We sought to clarify whether PPI-induced dysbiosis and worsening of the damage were due to a specific drug class effect of PPIs. Rabeprazole administration increased operational taxonomic unit numbers in the small intestines of C57BL/6 J mice, whereas the difference was not significant in the vonoprazan-treated group but exhibited a trend. Permutational multivariate analysis of variance of the unweighted UniFrac distances showed significant differences between vehicle- and vonoprazan- or rabeprazole-treated groups. L. johnsonii was the predominant microbial species, and the population ratio decreased after vonoprazan and rabeprazole administration. The vonoprazan- and rabeprazole-treated groups showed increased IND-induced damage. This high sensitivity to IND-induced damage was evaluated by transplantation with contents from the small intestine of mice treated with either vonoprazan or rabeprazole. Supplementation of L. johnsonii orally in mice treated with rabeprazole and vonoprazan prevented the increase in IND-induced small intestinal damage. In conclusion, both rabeprazole and vonoprazan aggravated NSAID-induced small intestinal injury by reducing the population of L. johnsonii in the small intestine via suppressing gastric acid secretion.


Asunto(s)
Disbiosis/inducido químicamente , Indometacina/efectos adversos , Intestino Delgado/lesiones , Lactobacillus johnsonii/aislamiento & purificación , Inhibidores de la Bomba de Protones/efectos adversos , Animales , Modelos Animales de Enfermedad , Disbiosis/microbiología , Trasplante de Microbiota Fecal , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Indometacina/administración & dosificación , Inyecciones Intraperitoneales , Intestino Delgado/efectos de los fármacos , Intestino Delgado/microbiología , Lactobacillus johnsonii/efectos de los fármacos , Lactobacillus johnsonii/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Inhibidores de la Bomba de Protones/administración & dosificación , Pirroles/administración & dosificación , Pirroles/efectos adversos , ARN Ribosómico 16S/genética , Rabeprazol/administración & dosificación , Rabeprazol/efectos adversos , Análisis de Secuencia de ADN , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos
2.
Benef Microbes ; 10(4): 473-482, 2019 Apr 19.
Artículo en Inglés | MEDLINE | ID: mdl-30931589

RESUMEN

Effective cultivation methods, total cost, and biomass preservation are key factors that have a significant impact on the commercialisation and effectiveness of probiotics, such as Lactobacillus. Sugar polymers, milk and whey proteins have been suggested as good additives for industrial preparations. Alternative compounds, such as phytophenols, are a more attractive option, given their potential benefits to human health. The overall goal of this study was to determine if the addition of blueberry phytophenols improves the survival of Lactobacillus johnsonii N6.2 during the freeze-drying process. The addition of blueberry aqueous extract (BAE) stimulated the growth of L. johnsonii under aerobic conditions and improved the stationary phase survival of the bacteria. Furthermore, the addition of BAE to the culture media improved the endurance of L. johnsonii N6.2 to freeze-drying stress, as well as to storage at 4 °C for up to 21 weeks. Moreover, blueberry extract performed more effectively as a lyophilising additive compared to skim milk and microencapsulation with whey protein/sodium alginate. In sum, this study demonstrates that BAE is an effective additive to increase the growth and survival of L. johnsonii N6.2 when added to the culture medium and/or used as a lyophilising preservative. Moreover, BAE or other polyphenols sources might likely enhance growth and increase survival of more probiotic lactic acid bacterial strains.


Asunto(s)
Arándanos Azules (Planta) , Aditivos Alimentarios , Liofilización , Lactobacillus johnsonii/fisiología , Probióticos , Aerobiosis , Arándanos Azules (Planta)/química , Aditivos Alimentarios/química , Aditivos Alimentarios/farmacología , Almacenamiento de Alimentos , Lactobacillus johnsonii/efectos de los fármacos , Lactobacillus johnsonii/crecimiento & desarrollo , Viabilidad Microbiana/efectos de los fármacos , Extractos Vegetales/química , Extractos Vegetales/farmacología , Polifenoles/química , Polifenoles/farmacología
3.
Elife ; 72018 03 27.
Artículo en Inglés | MEDLINE | ID: mdl-29580380

RESUMEN

Over the past century, soybean oil (SBO) consumption in the United States increased dramatically. The main SBO fatty acid, linoleic acid (18:2), inhibits in vitro the growth of lactobacilli, beneficial members of the small intestinal microbiota. Human-associated lactobacilli have declined in prevalence in Western microbiomes, but how dietary changes may have impacted their ecology is unclear. Here, we compared the in vitro and in vivo effects of 18:2 on Lactobacillus reuteri and L. johnsonii. Directed evolution in vitro in both species led to strong 18:2 resistance with mutations in genes for lipid biosynthesis, acid stress, and the cell membrane or wall. Small-intestinal Lactobacillus populations in mice were unaffected by chronic and acute 18:2 exposure, yet harbored both 18:2- sensitive and resistant strains. This work shows that extant small intestinal lactobacilli are protected from toxic dietary components via the gut environment as well as their own capacity to evolve resistance.


Asunto(s)
Microbioma Gastrointestinal/efectos de los fármacos , Intestino Delgado/microbiología , Lactobacillus johnsonii/efectos de los fármacos , Limosilactobacillus reuteri/efectos de los fármacos , Ácido Linoleico/toxicidad , Aceite de Soja/toxicidad , Animales , Farmacorresistencia Bacteriana , Lactobacillus johnsonii/crecimiento & desarrollo , Limosilactobacillus reuteri/crecimiento & desarrollo , Ratones , Mutación , Selección Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...